COVID‐19 and the increase in schizophrenia incidence in the future: A hypothesis and a serious warning

Pourfridoni, Mohammad; Askarpour, Hedyeh

doi:10.1002/hsr2.978

Cited by 6 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our case, at the 6-month and 1-year follow-up, the patient was in complete remission without any evidence of chronic psychosis. In view of current concerns regarding an increased risk of schizophrenia following COVID-19 [ 64 ], future follow-up cohort studies are highly needed.…”

Section: Discussion and Brief Review Of Literaturementioning

confidence: 99%

COVID-19-Associated Acute Psychotic Disorder—Longitudinal Case Report and Brief Review of Literature

et al. 2023

View full text Add to dashboard Cite

Even though since the beginning of the COVID-19 pandemic, the literature became more and more abundant on data and hypotheses about the various consequences on people’s lives, more clarity needs to be added to the existing information. Besides the stressful experiences related to the COVID-19 pandemic, SARS-CoV-2 infection has been proven to impact brain functioning through direct and indirect pathogenic mechanisms. In this context, we report a case of a patient presenting with a first episode of psychosis following COVID-19. In our case, a 28-year-old male patient with no personal or family psychiatric history developed psychotic symptoms (delusions, hallucinations, and disorganized behaviour) that required antipsychotic treatment and inpatient hospitalization one week after he was discharged from the hospital after COVID-19. At the six-month and one-year follow-up, the patient was in remission without any psychotic signs or symptoms. A brief review of the literature is also provided. The case presented in this article outlines the possibility that the post-COVD-19 recovery period might be a crucial time for the onset of acute psychotic disorder, and therefore, routine psychiatric assessments should be carried out during all phases of the disease. A clearer picture of the impact of the COVID-19 pandemic on mental health will most likely be revealed in the future as many consequences need long-term evaluation.

show abstract

Section: Discussion and Brief Review Of Literaturementioning

confidence: 99%

COVID-19-Associated Acute Psychotic Disorder—Longitudinal Case Report and Brief Review of Literature

et al. 2023

View full text Add to dashboard Cite

show abstract

“… 8 , 9 Protecting the mental health of these patients is therefore important not only for their own long-term health but also for controlling the pandemic. 10 , 11 …”

Section: Introductionmentioning

confidence: 99%

“… 12 It can be said that COVID‐19 can cause several changes in the human immune system that are known possible etiologies of schizophrenia. 11 Previous studies have shown that COVID-19 has various psychosocial effects on schizophrenia patients. 4 , 13 , 14 At the same time, SARS-CoV-2 infection might present as liver injury, kidney injury, cardiac failure and mitochondriopathy.…”

Section: Introductionmentioning

confidence: 99%

Abnormal Serum Biochemical Results and Mitochondrial Damage of Lymphocytes in Patients with Schizophrenia and SARS-CoV-2 Infection: A Retrospective Study

Zhang,

Shi,

Lin

et al. 2024

NDT

View full text Add to dashboard Cite

“…Coronavirus infection itself may exacerbate symptoms in people with schizophrenia, as coronaviruses may be associated with symptoms of psychosis through an immune-related mechanism [11]. It can be said that COVID-19 can cause several changes in the human immune system that are known possible etiologies of schizophrenia [12]. Previous studies have shown that COVID-19 has various psychosocial effects on schizophrenia patients [5,7,13].…”

Section: Introductionmentioning

confidence: 99%

Clinical and biochemical characteristics of schizophrenia patients with and without COVID-19: A retrospective study

Zhang,

Liu,

Shi

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Previous studies have shown that patients with mental diseases such as schizophrenia are at high risk of coronavirus disease 2019 (COVID-19). However, the clinical characteristics of patients with schizophrenia and COVID-19 remain unknown. The aim of this study was to investigate the differences in clinical biochemical values between schizophrenia patients with and without COVID-19. Methods We undertook an exploratory, retrospective review of patient data from Dec. 6, 2022, to Jan. 31, 2023. A total of 1696 inpatients with psychosis (921 schizophrenia patients and 775 diagnosed with other mental diseases) during this period were identified. Finally, 60 schizophrenia patients were enrolled in our study, and 20 of them were infected with syndrome coronavirus 2 (SARS-CoV-2). Results The serum biochemical levels, blood cell counts and single-cell mitochondrial mass (SCMM) of the T lymphocytes of all schizophrenia patients were analyzed. Schizophrenia patients with COVID-19 (SCZ-C) showed higher serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), creatinine (Cr), uric acid (UA), lactate dehydrogenase (LDH), myoglobin (Myo), and C-reactive protein (CRP) and platelet counts and a significant decrease in lymphocyte, monocyte, eosinophil, and basophil cell counts. In addition, positive correlations were found between the T-cell subpopulation counts and positive symptom scores on the Positive and Negative Syndrome Scale (PANSS). Conclusion Our study findings showed that schizophrenia patients with COVID-19 have a phenotype of mitochondrial damage in peripheral blood T lymphocytes and may have liver, heart and kidney damage compared with SARS-CoV-2-negative schizophrenia patients.

show abstract

COVID‐19 and the increase in schizophrenia incidence in the future: A hypothesis and a serious warning

Cited by 6 publications

References 18 publications

COVID-19-Associated Acute Psychotic Disorder—Longitudinal Case Report and Brief Review of Literature

COVID-19-Associated Acute Psychotic Disorder—Longitudinal Case Report and Brief Review of Literature

Abnormal Serum Biochemical Results and Mitochondrial Damage of Lymphocytes in Patients with Schizophrenia and SARS-CoV-2 Infection: A Retrospective Study

Clinical and biochemical characteristics of schizophrenia patients with and without COVID-19: A retrospective study

Contact Info

Product

Resources

About